CURES 'red flags' covered in San Francisco course

Dentists prescribe approximately 11 percent of prescription opioids annually in the U.S. With this in mind, CDA Public Affairs is sponsoring a course to be held at CDA Presents The Art and Science of Dentistry in San Francisco this August that will help dental professionals understand their role in drug diversion programs, including the use of California’s prescription drug monitoring program known as CURES, Controlled Substance Utilization Review and Evaluation System. All California prescribers with U.S. Drug and Enforcement Administration registrations were required to register for CURES 2.0 by July 1, 2016.

Dentists are strongly encouraged to consult CURES when considering prescribing a controlled substance for a new patient or a patient suspected of drug dependency. Under a new law, prescribers will soon be required to check a patient’s prescription history in CURES 2.0 prior to prescribing a Schedule II-IV substance in certain situations, with some exemptions.

Course attendees will receive instructions for accessing CURES 2.0 along with a review of legitimate medical purposes and many examples of what to watch out for — red flags for drug-seeking behaviors. Dentists will see a sample “patient/client activity” page from the CURES database and hear a patient scenario. With the scenario are questions prescribers should ask themselves or even the patient. The scenario becomes a discussion item for attendees: “What should you do?” and “What must you do?”

Clinical and Legal Considerations for Prescribing Controlled Substances” is presented by Michael J. Bundy, PharmD, DMD, MD, and Tony J. Park, PharmD, JD, and takes place Saturday, Aug. 26, from noon to 2:30 p.m. The course offers 2.5 core C.E. units and is open to the entire dental team on a first-come, first-served basis. The course will be audio recorded and made available for purchase after the convention for those who are unable to attend.

Learn more about this course via the CDA mobile app, the print version of the CDA Presents Program (mailed with the June issue of the CDA Journal) or the online program available at cdapresents.com/sf2017.

Related Items

It demonstrates airway and breathing complications, comes with a host of cardiac and circulation features, offers IV and intraosseous access, can respond to medical interventions — from nasotracheal intubation to surgical cricothyrotomy — and it talks back and is completely wireless. It’s the SimMan — and this August at CDA Presents The Art and Science of Dentistry in San Francisco, the dentist and entire dental team will have an opportunity to train with the high-fidelity simulation mannequin.

California prescribers who are registered with the U.S. Drug Enforcement Agency to prescribe, dispense or administer controlled substances must also register to access the state’s prescription drug monitoring program, CURES. A $6 annual ($12 biennial) fee is assessed with licensure renewal in order to maintain the database.

CDA has created a new online resource guide to help dentists meet requirements and follow best practices when prescribing opioids for the treatment of patients' dental pain. This resource is CDA's latest in ongoing efforts to address and combat California's opioid epidemic and ensure members have the most up-to-date information to maintain compliance in the dental practice.